Prostate Cancer, 2nd Edition

  • Jack Mydio
  • Ciril Godec
  • Published By:
  • ISBN-10: 0128005920
  • ISBN-13: 9780128005927
  • DDC: 616.99463
  • Grade Level Range: 11th Grade - College Senior
  • 672 Pages | eBook
  • Original Copyright 2015 | Published/Released March 2016
  • This publication's content originally published in print form: 2015

  • Price:  Sign in for price



This book presents a thorough overview of the prostate cancer disease, reviewing the biological processes, current treatments and scientific developments that may yield new treatments in the future. Each chapter has been written by internationally recognized specialists on prostate cancer epidemiology, genetic susceptibility, cancer metastases, prostate physiology, proteomics, new therapeutics, and clinical trials.

Table of Contents

Front Cover.
Half Title Page.
Title Page.
Copyright Page.
List of Contributors.
Etiology, Pathology, and Tumor Biology.
1: Population Screening for Prostate Cancer and Early Detection.
2: Inflammation and Infection in the Etiology of Prostate Cancer.
3: Androgen Receptor.
4: Novel Research on Fusion Genes and Next-Generation Sequencing.
5: Should Gleason Score 6 Still Be Called Cancer?.
6: High Grade Prostatic Intraepithelial Neoplasia and Atypical Glands.
7: Prostate Cancer in the Elderly.
8: Prostate Cancer and Other Primary Malignancies.
9: Biopsy Prophylaxis, Technique, Complications, and Repeat Biopsies.
10: Total and Free PSA, PCA3, PSA Density and Velocity.
11: Imaging in Localized Prostate Cancer.
Genetic Susceptibility And Hereditary Predisposition, Screening, And Counseling.
12: Prostate Cancer Prevention: Strategies and Realities.
13: Prostate-Specific Antigen Screening Guidelines.
14: Cancer of the Prostate: Incidence in the USA.
15: International Trends in Prostate Cancer.
16: Race, Ethnicity, Marital Status, Literacy, and Prostate Cancer Outcomes in the United States.
17: Hereditary Prostate Cancer.
18: Neuroendocrine Prostate Cancer.
19: Breast and Prostate Cancers: A Comparison of Two Endocrinologic Malignancies.
Prevention of Prostate Cancer.
20: Heart Healthy = Prostate Healthy and S.A.M. are the Ideal “Natural” Recommendations for Prostate Cancer.
21: Effects of Smoking, Alcohol, and Exercise on Prostate Cancer.
22: Environmental and Occupational Exposures and Prostate Cancer.
23: Level-1 Data from the REDUCE Study and the PCPT Data.
Conservative Management.
24: Decision Support for Low-Risk Prostate Cancer.
25: Active Surveillance: Rationale, Patient Selection, Follow-up, and Outcomes.
26: Preoperative Risk Assessment.
27: Is Surgery Still Necessary for Prostate Cancer?.
28: Indications for Pelvic Lymphadenectomy.
29: The Surgical Anatomy of the Prostate.
30: Radical Retropubic Prostatectomy.
31: Radiation-Resistant Prostate Cancer and Salvage Prostatectomy.
32: Postradical Prostatectomy Incontinence.
33: Prognostic Significance of Positive Surgical Margins and Other Implications of Pathology Report.
34: Open Versus Robotic Prostatectomy.
35: The Technique of Robotic Nerve-Sparing Prostatectomy.
36: Anterior Approach to Robotic Radical Prostatectomy.
37: Posterior Approach to Robotic-Assisted Laparoscopic Radical Prostatectomy.
38: The Technique of Robotic Nerve Sparing Prostatectomy. - Extraperitoneal Approach.
39: Clinical and Pathologic Staging of Prostate Cancer.
40: Management of Bladder Neck Contracture in the Prostate Cancer Survivor.
41: Reimbursement for Prostate Cancer Treatment.
Radiation Therapy.
42: Fundamentals of Radiation Treatment for Prostate Carcinoma – Techniques, Radiation Biology, and Evidence Base.
43: Radiation with Hormonal Therapy.
44: Brachytherapy for Prostate Cancer: An Overview.
45: Intensity Modulated Radiotherapy and Image Guidance.
46: Proton Beam Therapy.
47: Radiotherapy After Radical Prostatectomy: Adjuvant Versus Salvage Approach.
48: Emerging Modalities in Radiation Therapy for Prostate Cancer.
Clinical Dilemmas.
49: Management of PSA Recurrences After Radical Prostatectomy.
50: Salvage Therapy for Locally Recurrent Prostate Cancer After External Beam Radiation Therapy.
51: Management of Locally Advanced (Nonmetastatic) Prostate Cancer.
Advanced Prostate Cancer.
52: Androgen Deprivation Therapy: Appropriate Patients, Timing to Initiate ADT, and Complications.
53: Bone Health in Prostate Cancer.
54: Castration Resistant Prostate Cancer: Role of Chemotherapy.
55: Antiandrogen Monotherapy in the Treatment of Prostate Cancer.
56: Sipuleucel-T – A Model for Immunotherapy Trial Development.
57: Second-Line Hormonal for Castrate-Resistant Prostate Cancer.
Cryoablation, Hifu and Focal Therapy.
58: Salvage Cryoablation of the Prostate.
59: High-Intensity Focused Ultrasound.
60: Focal Therapy for Prostate Cancer.
61: Quality of Life: Impact of Prostate Cancer and Its Treatment.
62: Impact of Prostate Cancer Treatments on Sexual Health.
Govermental Policies.
63: Coding and Billing for Diagnosis and Treatment of Prostate Cancer.
64: Health Policy for Prostate Cancer: PSA Screening as Case Study.
65: Legal Implications of Prostate Cancer Screening.
New Horizons for Prostate Cancer.
66: New Markers for Prostate Cancer Detection and Prognosis.
67: Testosterone Therapy in Hypogonadal Men with Prostate Cancer.
Subject Index.